APVO
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Aptevo advances its next-generation trispecific candidate toward clinical developmentSep 24, 2026
- Aptevo files patent to strengthen its dual-targeting solid tumor immunotherapy strategyJul 27, 2026
- Aptevo reported strong clinical outcomes with high benefit and remission rates in frontline AML patients, outperforming benchmarksMay 6, 2026
- Mipletamig showed an 86% clinical benefit rate with no CRS as evaluable AML patient data increased significantlyMar 10, 2026
- Aptevo debuts first trispecific antibody candidate, APVO451, with preclinical data demonstrating immune activation in hard-to-treat solid tumorsNov 10, 2025